MNMD241220C22000
- 0.15
- 0.000.00%
Mind Medicine Newsroom
MindMed Scientific Presentations at American College of Neuropsychopharmacology (ACNP) 2024 Congress
MindMed Awarded Innovation Passport Designation By United Kingdom Innovative Licensing And Access Pathway Steering Group For MM120 Orally Disintegrating Tablet For Generalized Anxiety Disorder
Express News | Mind Medicine: Awarded Innovation Passport Designation by UK Ilap Steering Group for Mm120 Odt for Generalized Anxiety Disorder
MindMed Awarded Innovation Passport Designation by the United Kingdom (UK) Innovative Licensing and Access Pathway (ILAP) Steering Group for MM120 Orally Disintegrating Tablet (ODT) for Generalized Anxiety Disorder (GAD)
Express News | MindMed Appoints Javier Muniz, M.d., as Vice President of Research and Development Strategy
MindMed Announces New Employee Inducement Grants
RBC Capital Maintains Mind Medicine(MNMD.US) With Buy Rating, Maintains Target Price $21
RBC Capital Remains a Buy on Mind Medicine (MNMD)
MindMed Appoints Gregg Pratt, Ph.D. as Chief Regulatory and Quality Assurance Officer
Is Mind Medicine (MNMD) the Best Multibagger Stock to Buy Heading Into 2025?
RFK and the 'MAHA Trade': Vaccine Makers Down, Psychedelic Shares up
Mind Medicine (MindMed) Inc.'s (NASDAQ:MNMD) Market Cap Touched US$601m Last Week, Benefiting Both Retail Investors Who Own 41% as Well as Institutions
AI And Psychedelics: A Marriage Made In Heaven For Mental Health Care?
MindMed to Participate in Upcoming Investor Conferences
Mind Medicine Analyst Ratings
Optimistic Outlook for Mind Medicine Amidst Promising Phase 3 Developments and Robust Financial Health
Maxim Group Maintains Mind Medicine(MNMD.US) With Buy Rating, Maintains Target Price $18
Oppenheimer Maintains Mind Medicine(MNMD.US) With Buy Rating, Maintains Target Price $20
H.C. Wainwright Maintains Mind Medicine(MNMD.US) With Buy Rating, Maintains Target Price $55
Mind Medicine Shares Are Trading Higher After the Company Reported Better-than-expected Q3 EPS Results.